Neurocrine Biosciences, Inc. (NBIX) to Post FY2018 Earnings of $0.30 Per Share, Jefferies Financial Group Forecasts

Share on StockTwits

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Research analysts at Jefferies Financial Group issued their FY2018 earnings per share estimates for Neurocrine Biosciences in a research report issued to clients and investors on Sunday, February 3rd. Jefferies Financial Group analyst B. Amin expects that the company will earn $0.30 per share for the year. Jefferies Financial Group also issued estimates for Neurocrine Biosciences’ FY2019 earnings at $1.90 EPS, FY2020 earnings at $4.11 EPS, FY2021 earnings at $5.20 EPS and FY2022 earnings at $7.22 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.18 by $0.01. The business had revenue of $131.49 million for the quarter, compared to analyst estimates of $132.32 million. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. The business’s quarterly revenue was up 39.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.07 EPS.

Several other equities analysts have also weighed in on NBIX. Cantor Fitzgerald restated an “overweight” rating on shares of Neurocrine Biosciences in a report on Wednesday. Oppenheimer set a $105.00 target price on shares of Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, January 29th. HC Wainwright restated a “buy” rating on shares of Neurocrine Biosciences in a report on Wednesday, January 30th. ValuEngine lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 15th. Finally, Robert W. Baird reduced their target price on shares of Neurocrine Biosciences from $131.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, December 13th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $101.45.

NASDAQ:NBIX opened at $87.78 on Wednesday. The firm has a market cap of $8.02 billion, a P/E ratio of -54.19, a price-to-earnings-growth ratio of 2.52 and a beta of 1.89. Neurocrine Biosciences has a twelve month low of $64.72 and a twelve month high of $126.98.

In related news, Director Richard F. Pops sold 4,124 shares of Neurocrine Biosciences stock in a transaction on Monday, November 26th. The shares were sold at an average price of $91.37, for a total transaction of $376,809.88. Following the sale, the director now owns 29,512 shares of the company’s stock, valued at approximately $2,696,511.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard F. Pops sold 4,123 shares of Neurocrine Biosciences stock in a transaction on Monday, November 12th. The stock was sold at an average price of $103.30, for a total transaction of $425,905.90. Following the sale, the director now directly owns 33,636 shares in the company, valued at approximately $3,474,598.80. The disclosure for this sale can be found here. Insiders have sold a total of 11,282 shares of company stock worth $1,064,891 in the last ninety days. 4.30% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Neurocrine Biosciences by 0.5% in the 2nd quarter. FMR LLC now owns 13,451,201 shares of the company’s stock worth $1,321,446,000 after purchasing an additional 60,325 shares during the last quarter. Vanguard Group Inc increased its position in shares of Neurocrine Biosciences by 2.7% in the 3rd quarter. Vanguard Group Inc now owns 7,772,236 shares of the company’s stock worth $955,597,000 after purchasing an additional 204,065 shares during the last quarter. Perceptive Advisors LLC increased its position in shares of Neurocrine Biosciences by 1.3% in the 3rd quarter. Perceptive Advisors LLC now owns 4,777,254 shares of the company’s stock worth $587,363,000 after purchasing an additional 62,004 shares during the last quarter. First Trust Advisors LP increased its position in shares of Neurocrine Biosciences by 4.2% in the 3rd quarter. First Trust Advisors LP now owns 1,020,857 shares of the company’s stock worth $125,514,000 after purchasing an additional 41,186 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Neurocrine Biosciences by 60.5% in the 3rd quarter. Victory Capital Management Inc. now owns 605,135 shares of the company’s stock worth $74,402,000 after purchasing an additional 228,163 shares during the last quarter. 97.82% of the stock is owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Featured Article: Intrinsic Value

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply